View Cart ()
Your cart is empty
-
NEW: Sponsored, no-charge testing for individuals suspected of having a long-chain fatty acid oxidation disorder. Learn more >
-
NEW: Sponsored, no-charge testing for individuals suspected of having a neurotransmitter disorder. Learn more >
Follow our progress.
Milestones in our journey to reinvent genetic testing.
Back to full list
Press Releases
Joining forces with Locus Development
August 08, 2012
Genomic Health Announces Second Quarter 2012 Financial Results and Business Progress
- Product Revenue Increased 13% Compared with Prior Year
- Delivered Net Income of $1.8 Million
- Began Offering Oncotype DX® Colon Cancer Test for Stage III Patients
- Combined Invitae with Locus Development to Create Independent Genetics Company
- Conference Call Today at 4:30 p.m. ET
REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2012.
EXCERPT FROM PRESS RELEASE REGARDING ...
Company Formation
February 06, 2012
Genomic Health Announces Formation of New Genetics Subsidiary
REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions. The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013. The new venture will be led by Randy Scott, who in ...
